showed that increased expression of phosphorylated ERBB3 is a key resistance mechanism in FGFR3-dependent bladder cancer and that dual targeting of FGFR3 and ERBB3 delayed the reactivation of pERBB3 and enhanced FGFR inhibitor efficacy (74). This evidence concerns the gene ERBB3 and urinary bladder carcinoma.